Eisai and Biogen’s phase 3 Alzheimer’s win puts amyloid back in the driver’s seat, for now

 By Max Bayer

Eisai and Biogen's recent phase 3 victory has once again placed the spotlight on amyloid beta. A slate of late-stage drugs, including lecanemab, are targeting amyloid plaque buildup to treat Alzheimer's.